{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+hydrochloride&page=3", "query": { "intervention": "Irinotecan hydrochloride", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 895, "total_pages": 90, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+hydrochloride&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+hydrochloride&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:33:00.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02044120", "title": "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma" ], "interventions": [ { "name": "niraparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 34, "start_date": "2014-05", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02044120" }, { "nct_id": "NCT00006015", "title": "Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2000-05", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006015" }, { "nct_id": "NCT00036517", "title": "Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Diarrhea" ], "interventions": [ { "name": "PHY906", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhytoCeutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2002-02", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 3, "location_summary": "West Haven, Connecticut • New York, New York • Greenville, South Carolina", "locations": [ { "city": "West Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036517" }, { "nct_id": "NCT02405585", "title": "Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable" ], "interventions": [ { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-04", "completion_date": "2016-07-30", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 4, "location_summary": "Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405585" }, { "nct_id": "NCT07214298", "title": "Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pegcetacoplan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2026-02-16", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07214298" }, { "nct_id": "NCT03606967", "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Personalized Synthetic Long Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2021-04-13", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 30, "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606967" }, { "nct_id": "NCT02013336", "title": "Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent or Refractory Solid Tumors", "Ewing Sarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Osteosarcoma" ], "interventions": [ { "name": "MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "South Plains Oncology Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "12 Months to 20 Years" }, "enrollment_count": 30, "start_date": "2013-12", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 6, "location_summary": "Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 3 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013336" }, { "nct_id": "NCT06518538", "title": "Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Stage IV" ], "interventions": [ { "name": "CPI-613, modified Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cornerstone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2024-08-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518538" }, { "nct_id": "NCT02782182", "title": "Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-06-28", "completion_date": "2018-03-29", "has_results": false, "last_update_posted_date": "2019-03-19", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782182" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-07T18:33:00.995Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" } ] }